Protara Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Protara Therapeutics (Nasdaq: TARA), a clinical-stage company focused on developing transformative therapies for cancer and rare diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management will deliver a presentation on Thursday, January 16, 2025, at 7:30 am PT in San Francisco.

The presentation will be accessible through a live webcast on the Events and Presentations section of Protara's investor relations website at https://ir.protaratx.com. Interested parties who cannot attend in person can view the presentation online, and a recording will be available for a time afterward.

NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the 43^rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025, at 7:30 am PT in San Francisco.

A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcast will be archived for a limited time following the presentation.

About Protara Therapeutics, Inc.

Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG), as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit www.protaratx.com.

Company Contact:

Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836

FAQ

When is Protara Therapeutics (TARA) presenting at the 2025 J.P. Morgan Healthcare Conference?

Protara Therapeutics will present on Thursday, January 16, 2025, at 7:30 am PT in San Francisco.

How can investors watch Protara Therapeutics' (TARA) J.P. Morgan Healthcare Conference presentation?

Investors can watch the presentation through a live webcast available on Protara's investor relations website at https://ir.protaratx.com in the Events and Presentations section.

Will Protara Therapeutics' (TARA) J.P. Morgan Healthcare Conference presentation be available for replay?

Yes, the webcast will be archived and available for replay for a time following the presentation on Protara's website.

What therapeutic areas does Protara Therapeutics (TARA) focus on?

Protara Therapeutics focuses on developing transformative therapies for the treatment of cancer and rare diseases.